Aberrations in plasma phospholipid fatty acids in lung cancer patients

Lipids

Volumn 47, Issue 4, 2012, Pages 363-369

  Murphy, Rachel A ^a   Bureyko, Taylor F ^a   Mourtzakis, Marina ^b   Chu, Quincy S ^a   Thomas Clandinin, M ^a   Reiman, Tony ^c   Mazurak, Vera C ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Eicosapentaenoic fatty acid; Lung cancer; N 3 fatty acids; Nutrition; Phospholipids; Plasma lipids

Indexed keywords

ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; CARBOPLATIN; CISPLATIN; DOCOSAHEXAENOIC ACID; FATTY ACID; GEMCITABINE; ICOSAPENTAENOIC ACID; LINOLEIC ACID; NAVELBINE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PALMITIC ACID; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; STEARIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFECT; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; LIPID COMPOSITION; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; TREATMENT DURATION; WEIGHT REDUCTION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; BODY MASS INDEX; CANADA; FATTY ACIDS; FEMALE; HUMANS; LIPID METABOLISM; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHOLIPIDS; SURVIVAL RATE; WEIGHT LOSS;

EID: 84863429179     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-011-3641-2     Document Type: Article

References (25)

1. Rydén M, Agustsson T, Laurencikiene J, Britton T, Sjölin E, Isaksson B, Permert J, Arner P (2008) Lipolysis-not inflammation, cell death, or lipogenesis-is involved in adipose tissue loss in cancer cachexia. Cancer 113:1695-1704
2. Douglas RG, Shaw JH (1997) Metabolic effects of cancer. Br J Surg 77:246-543
3. Clandinin MT, Van Aerde JE, Parrott A, Field CJ, Euler AR, Lien EL (1997) Assessment of the efficacious dose of arachidonic and docosahexaenoic acids in preterm infant formulas: fatty acid composition of erythrocyte membrane lipids. Pediatr Res 42:819-825
4. Pratt VC, Tredget EE, Clandinin MT, Field CJ (2001) Fatty acid content of plasma lipids and erythrocyte phospholipids are altered following burn injury. Lipids 36:675-682 (Pubitemid 32777012)
5. 13C-docosahexaenoic acid in the elderly. Nutr Metab 8:5
6. McClinton S, Moffat LE, Horrobin DF, Manku MS (1991) Abnormalities of essential fatty acid distribution in the plasma phospholipids of patients with bladder cancer. Br J Cancer 63:314-367
7. Chaudry A, McClinton S, Moffat LE, Wahle KW (1991) Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br J Cancer 64:1157-1160
8. Zuijdgeest-van Leeuwen SD, van der Heijden MS, Rietveld T, van den Berg JW, Tilanus HW, Burgers JA, Wilson JH, Dagnelie PC (2002) Fatty acid composition of plasma lipids in patients with pancreatic, lung and oesophageal cancer in comparison with healthy subjects. Clin Nutr 21:225-230 (Pubitemid 34846802)
9. Pratt VC, Watanabe S, Bruera E, Mackey J, Clandinin MT, Baracos VE, Field CJ (2002) Plasma and neutrophil fatty acid composition in advanced cancer patients and response to fish oil supplementation. Br J Cancer 87:1370-1378 (Pubitemid 36044310)
10. Cvetković Z, Vucić V, Cvetković B, Petrović M, Ristić-Medić D, Tepsić J, Glibetić M (2010) Abnormal fatty acid distribution of the serum phospholipids of patients with non-Hodgkin lymphoma. Ann Hematol 89:775-782
11. Taylor LA, Arends J, Hodina AK, Unger C, Massing U (2007) Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis 6:17
12. Baburina I, Jackowski S (1999) Cellular responses to excess phospholipid. J Biol Chem 274(14):9400-9408
13. Murphy RA, Wilke MS, Perrine M, Pawlowicz M, Mourtzakis M, Lieffers JR, Maneshgar M, Bruera E, Clandinin MT, Baracos VE, Mazurak VC (2010) Loss of adipose tissue and plasma phospholipids: relationship to survival in advanced cancer patients. Clin Nutr 29:482-487
14. Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC (2011) Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 117:1775-1782
15. Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC (2011) Supplementation with fish oil increases firstline chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer 117:3774-3780
16. Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE, O'Brien ME (2004) Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 90:1905-1911 (Pubitemid 38746329)
17. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2009) American joint committee on cancer staging manual, 7th edn. Springer, New York
18. WHO (2000) Obesity: preventing and managing the global epidemic. World Health Organization, Geneva
19. Ottery FD (1996) Definition of standardized nutritional assessment and interventional pathways in oncology. Nutrition 12:S15-S19
20. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655 (Pubitemid 13149996)
21. Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA, Coebergh JW (1998) Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a populationbased study. Lung Cancer 21:105-113 (Pubitemid 29028028)
22. Murphy RA, Mourtzakis M, Chu QS, Reiman T, Mazurak VC (2010) Skeletal muscle depletion is associated with reduced plasma (n-3) fatty acids in non-small cell lung cancer patients. J Nutr 140:1602-1606
23. Raffelt K, Moka D, Sullentrop F, Dietlein M, Hahn J, Schicha H (2000) Systemic alterations in phospholipid concentrations of blood plasma in patients with thyroid carcinoma: an in vitro (31) P high-resolution NMR study. NMR Biomed 13:8-13 (Pubitemid 30136997)
24. Kuliszkiewicz-Janus M, Janus W, Baczynski S (1996) Application of 31P NMR spectroscopy in clinical analysis of changes of serum phospholipids in leukemia, lymphoma and some other non-haematological cancers. Anticancer Res 16:1587-1594 (Pubitemid 26257832)
25. Peters BG (1994) An overview of chemotherapy toxicities. Top Hosp Pharm Manage 14:59-88